海思科(002653.SZ)：苯磺酸克利加巴林胶囊新适应症上市许可申请获受理

智通财经网07-13

智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的创新药苯磺酸克利加巴林胶囊新适应症上市许可申请《受理通知书》，此次获得受理的是本品用于治疗成人神经病理性疼痛适应症的上市许可申请。

苯磺酸克利加巴林胶囊是公司自主开发的一个全新的具有独立知识产权的第三代电压门控钙通道调节剂，其可通过高亲和力结合神经元突触前膜的α₂δ亚基，抑制钙离子内流，减少谷氨酸、去甲肾上腺素和P物质等兴奋性神经递质的释放，从而缓解中枢敏化，具有抗癫痫、镇痛和抗焦虑等活性。

更多港股重磅资讯，下载智通财经app

更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651586119?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-13 19:52","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2651586119","market":"sg","top_or_hot":-1,"title":"海思科(002653.SZ)：苯磺酸克利加巴林胶囊新适应症上市许可申请获受理","media":"智通财经网","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/002653\">海思科</a>(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的创新药苯磺酸克利加巴林胶囊新适应症上市许可申请《受理通知书》，此次获得受理的是本品用于治疗成人神经病理性疼痛适应症的上市许可申请。</p><p>苯磺酸克利加巴林胶囊是公司自主开发的一个全新的具有独立知识产权的第三代电压门控钙通道调节剂，其可通过高亲和力结合神经元突触前膜的α₂δ亚基，抑制钙离子内流，减少谷氨酸、去甲肾上腺素和P物质等兴奋性神经递质的释放，从而缓解中枢敏化，具有抗癫痫、镇痛和抗焦虑等活性。</p><p>更多港股重磅资讯，下载智通财经app</p><p>更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)</p> </body></html>","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海思科(002653.SZ)：苯磺酸克利加巴林胶囊新适应症上市许可申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海思科(002653.SZ)：苯磺酸克利加巴林胶囊新适应症上市许可申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/002653\">海思科</a>(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的创新药苯磺酸克利加巴林胶囊新适应症上市许可申请《受理通知书》，此次获得受理的是本品用于治疗成人神经病理性疼痛适应症的上市许可申请。</p><p>苯磺酸克利加巴林胶囊是公司自主开发的一个全新的具有独立知识产权的第三代电压门控钙通道调节剂，其可通过高亲和力结合神经元突触前膜的α₂δ亚基，抑制钙离子内流，减少谷氨酸、去甲肾上腺素和P物质等兴奋性神经递质的释放，从而缓解中枢敏化，具有抗癫痫、镇痛和抗焦虑等活性。</p><p>更多港股重磅资讯，下载智通财经app</p><p>更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)</p> </body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1466798.html\">智通财经网</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002653","symbol_name":"海思科","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1466798.html","article_id":"2651586119","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651586119","pubTimestamp":1783943525,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，海思科 发布公告，公司于近日收到国家药品监督管理局下发的创新药苯磺酸克利加巴林胶囊新适应症上市许可申请《受理通知书》，此次获得受理的是本品用于治疗成人神经病理性疼痛适应症的上市许可申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"002653":"海思科","BK0188":"融资融券","BK0033":"西藏振兴","BK0077":"质押式回购","IPOS":"Renaissance International IPO ETF","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"Haisco (002653.SZ): Application for marketing authorization for new indications of cligabalin besylate capsules accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002653":1.5,"IPOS":1.5},"content_text":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的创新药苯磺酸克利加巴林胶囊新适应症上市许可申请《受理通知书》，此次获得受理的是本品用于治疗成人神经病理性疼痛适应症的上市许可申请。苯磺酸克利加巴林胶囊是公司自主开发的一个全新的具有独立知识产权的第三代电压门控钙通道调节剂，其可通过高亲和力结合神经元突触前膜的α₂δ亚基，抑制钙离子内流，减少谷氨酸、去甲肾上腺素和P物质等兴奋性神经递质的释放，从而缓解中枢敏化，具有抗癫痫、镇痛和抗焦虑等活性。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651586119","isCrawlerRequest":true}